Literature DB >> 17167952

Risk of tuberculous infection in an indigenous population from Amazonia, Brazil.

P C Basta1, C E A Coimbra, L A B Camacho, R V Santos.   

Abstract

SETTING: Suruí Indians, Amazonia, Brazil.
OBJECTIVE: To estimate the prevalence and the annual risk of infection (ARI) of tuberculosis (TB) in an indigenous population in Brazil.
METHODS: We applied a method to estimate the prevalence of TB infection in populations with high bacille Calmette-Guérin (BCG) vaccine coverage. The method consisted of comparing levels of skin test reactivity in individuals tested with purified protein derivative (PPD) before and after stimulation with intradermal BCG. Fieldwork was carried out among the Suruí Indians (n = 993) in two phases, 3 months apart.
RESULTS: A total of 645 subjects were tested. In pre-BCG revaccination, tuberculin skin test (TST) indurations averaged 5.9 mm (33.5% > or =10 mm). In post-BCG revaccination TST, indurations averaged 9.4 mm (48.7% > or =10 mm). Conversion from non-reactor to reactor was 54.4%. The ARI ranged from 1.2% to 2.2%. In the logistic regression, age and history of TB were the strongest independent predictors of TB infection. BCG scar and the number of individuals per house were also associated with infection.
CONCLUSION: Tuberculous transmission is very high in the Suruí, surpassing the ARI reported for Brazil (0.6%). The epidemiology of TB in this indigenous population is related to unfavourable social and economic conditions, as well as to deficient health care services.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167952

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Ethnic and Racial Inequalities in Notified Cases of Tuberculosis in Brazil.

Authors:  Paulo Victor de Sousa Viana; Maria Jacirema Ferreira Gonçalves; Paulo Cesar Basta
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

2.  Therapeutic itineraries and explanations for tuberculosis: an indigenous perspective.

Authors:  Laura Maria Vidal Nogueira; Elizabeth Teixeira; Paulo Cesar Basta; Maria Catarina Salvador da Motta
Journal:  Rev Saude Publica       Date:  2015-12-31       Impact factor: 2.106

3.  Impact of latent infection treatment in indigenous populations.

Authors:  Lucia Suemi Yuhara; Flávia Patussi Correia Sacchi; Julio Croda
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

4.  Incidence and transmission patterns of tuberculosis among indigenous populations in Brazil.

Authors:  Eunice Atsuko Cunha; Lucilaine Ferrazoli; Lee W Riley; Paulo Cesar Basta; Michael Robert Honer; Rosalia Maia; Izaias Pereira da Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11-04       Impact factor: 2.743

5.  The Socioeconomic Factors and the Indigenous Component of Tuberculosis in Amazonas.

Authors:  Daniel Barros de Castro; Rosemary Costa Pinto; Bernardino Cláudio de Albuquerque; Megumi Sadahiro; José Ueleres Braga
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

6.  Factors associated with TB in an indigenous population in Brazil: the effect of a cash transfer program.

Authors:  Jocieli Malacarne; Ida Viktoria Kolte; Lais Picinini Freitas; Jesem Douglas Yamall Orellana; Maximiliano Loiola Ponte de Souza; Reinaldo Souza-Santos; Paulo Cesar Basta
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-10-25       Impact factor: 1.846

7.  Tuberculosis incidence inequalities and its social determinants in Manaus from 2007 to 2016.

Authors:  Daniel Barros de Castro; Elvira Maria Godinho de Seixas Maciel; Megumi Sadahiro; Rosemary Costa Pinto; Bernardino Cláudio de Albuquerque; José Ueleres Braga
Journal:  Int J Equity Health       Date:  2018-12-29

8.  Genetic polymorphism and immune response to tuberculosis in indigenous populations: a brief review.

Authors:  Renata Maronna Praça Longhi; Verônica Marques Zembrzuski; Paulo Cesar Basta; Julio Croda
Journal:  Braz J Infect Dis       Date:  2013-05-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.